Results 41 to 50 of about 3,561,997 (213)
Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. [PDF]
, 2011 BACKGROUND: Somatic mutations in phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) are frequent in breast tumours and have been associated with oestrogen receptor (ER) expression, human epidermal growth factor receptor-2 overexpression, lymph ...Dite, G S, S Chanock, Noh, D-Y., Severi, G., Sangrajrang, S., Hein, R, Yoo, K-Y, J Wang, Wang, J., Pooley, K A, Anton-Culver, H., Rogov, Y.I., A Ziogas, Hein, A, Kosma, V.M., Brock, I W, S Manoukian, Meindl, A., S Sangrajrang, Dunning, A.M., R L Milne, Bartrar, CR, R Winqvist, S S Cross, Perez, J.I.A., Anton Culver, H., Ekici, A. B., Garcia Closas, M., Noh, D.Y., G G Giles, M W Beckmann, Silva, I. dos Santos, Hopper, JL, Broeks, A., Vachon, C M, N Johnson, Hopper, J L, Humphreys, M K, Bruening, T., Wang-Gohrke, S., Tollenaar, Robert A. E. M., Cross, SS, Kosma, V-M, Johnson, N., Bonanni, B, Milne, R L, Vachon, CM, M Bremer, Sawyer, E, Kataja, V, Mulligan, A.M., Easton, D F, Kosma, V-M., Chenevix Trench, G., P Schürmann, A Miron, L Baglietto, Miron, A, Lindblom, A., E M John, I W Brock, McKay, J, Kang, D., Bogdanova, N, Johnson, N, Apicella, C., Garcia-Closas, M., Van 't Veer, L. J., Hartikainen, J, Pylkaes, K., G S Dite, P Brennan, Hopper, J. L., Van 't Veer, LJ, Pooley, KA, Fredericksen, Z, Milne, R.L., Hopper, J.L., Cox, A, Pooley, K. A., Hillemanns, P., Wang-Gohrke, S, Kerin, M.J., John, E M, Rogov, Y. I., Zalutsky, J. V., Olson, J, McLean, CA, Anton-Culver, H, G D Thomas, Pooley, K.A., Hunter, D J, Grip, M, V-M Kosma, A Meindl, X Wang, N Bogdanova, BAGLIETTO, LAURA, Tomlinson, I, E Sawyer, Giles, GG, A M Dunning, Antonenkova, N, Pérez, JA, Schmidt, M K, Giles, G G, N Antonenkova, B Bonanni, Pharoah, P.P., Southey, M C, Chenevix-Trench, G, Invest, kConFab, GENICA Network, Schmidt, M. K., Hunter, DJ, Knight, J.A., Ko, YD, Mulligan, A M, Baglietto, L, Rogov, YI, V Gabrieau, Couch, FJ, Beckmann, M W, Knight, J A, Fasching, PA, J Peto, Meindl, A, Severi, G, Gibson, L., Burwinkel, B., Y I Rogov, Benítez, J, J McKay, Tomlinson, Ian, John, E. M., P P Pharoah, Lissowska, J, Noh, DY, Brüning, T., D-Y Noh, Glendon, G., Peterlongo, P, Noh, D. Y., Fredericksen, Z., Milne, RL, Beckmann, MW, Cross, S.S., Kosel, M, Manoukian, S., Schürmann, P, Chanock, S., Cerhan, J, Jukkola-Vuorinen, A, Fasching, P A, Australian Ovarian Cancer Study Group, Hoover, R. N., Vachon, C. M., I Andrulis, Rogov, Y I, Schmidt, M.K., H Anton-Culver, Dörk, T., P Hillemanns, Giles, G.G., Ekici, A B, Hoover, R.N., Schmutzler, RK, F J Couch, Australian Ovarian Cancer Study Gr, Peto, J., C Apicella, Couch, F.J., Hillemanns, P, Mannermaa, A., Brock, I.W., J Chang-Claude, Pylkäs, K, Van 't Veer, L.J., Cross, S. S., Chen, X, Winqvist, R, Hamann, U., Chang-Claude, J., Brennan, P, Baglietto, L., Kosma, V. M., Beckmann, M. W., Veer, L.J. van 't, Wang, X., kConFab Invest, Van T Veer, LJ, Van 't Veer, L. J., Dite, GS, S Margolin, Couch, F J, Jukkola-Vuorinen, A., Bartrar, C R, Dörk, T, Bremer, M, Hein, A., Dunning, A M, D Kang, D J Hunter, Manoukian, S, González-Neira, A, Doerk, T., Benitez, J., Thomas, GD, Sawyer, E., Hamann, U, T Dörk, V Kataja, Thomas, G. D., Dunning, A. M., Milne, R. L., I dos Santos Silva, Ko, Y D, A González-Neira, Tomlinson, I., Zalutsky, J V, M Grip, McLean, C A, Apicella, C, Gonzalez-Neira, A., Schmutzler, R. K., Pharoah, P P, null null, I Tomlinson, G Glendon, Stevens, K N, L J Van ‘t Veer, Schuermann, P., R N Hoover, Mclean, C. A., John, EM, Bartrar, C.R., Hunter, D.J., Mulligan, AM, C R Bartrar, Wang, J, Fasching, P.A., Ekici, A.B., Southey, M. C., Van ‘t Veer, LJ, Ziogas, A, Zalutsky, JV, Pérez, Ji Arias, Lissowska, J., Wang, X, Hoover, RN, M Garcia-Closas, Dunning, AM, Broeks, A, Burwinkel, B, Brock, IW, John, E.M., Easton, DF, Knight, J. A., M K Humphreys, Antonenkova, N., J A Knight, Tollenaar, RAEM, Kang, D, Mulligan, A. M., Kerin, M. J., Chang Claude, J., K-Y Yoo, M C Southey, Giles, G. G., Miron, A., Olson, J., Vachon, C.M., Humphreys, MK, Southey, M.C., S Wang-Gohrke, Chang-Claude, J, J Olson, Sangrajrang, S, Mckay, J., A Cox, Silva, I.D.S., V S Pankratz, Brennan, P., A B Ekici, Noh, D-Y, Jukkola Vuorinen, A., X Chen, Bremer, M., Ziogas, A., Pankratz, V. S., G Elliott, Schmutzler, R.K., Cerhan, J., Ekici, AB, Group, AOCS, Couch, F. J, K N Stevens, Van ‘t Veer, L J, Network, GENICA, A Broeks, A Mannermaa, A Lindblom, L Bernard, Peto, J, dos Santos Silva, I, M Kosel, Bonanni, B., A Jukkola-Vuorinen, Elliott, G., B Burwinkel, L Gibson, Easton, D. F., Yoo, KY, Knight, JA, Z Fredericksen, Grip, M., Gabrieau, V, M J Kerin, Peterlongo, P., Hoover, R N, Beckmann, M.W., J Cerhan, Bogdanova, N., Schürmann, P., Couch, F. J., Yoo, K.Y., R K Schmutzler, Gibson, L, J L Hopper, Lindblom, A, J Benítez, Kosel, M., C M Vachon, G Severi, González Neira, A., Margolin, S., K A Pooley, Humphreys, M. K., Pharoah, P. P., Stevens, K. N., Southey, MC, Brüning, T, Pharoah, PP, Dite, G. S., P Peterlongo, Bartrar, C. R., Elliott, G, A Hein, Kerin, MJ, Yoo, K-Y., Hartikainen, J., Pérez, J. A., R A E M Tollenaar, Dite, G.S., JI Arias Pérez, Garcia-Closas, M, Kosma, VM, Tollenaar, RA, G Chenevix-Trench, Bernard, L., Brock, I. W., Kerin, M J, Pankratz, V S, dos Santos Silva, I., Thomas, G D, J Hartikainen, Stevens, K.N., A M Mulligan, Wang Gohrke, S., Perez, J. I. Arias, Y D Ko, D F Easton, Chanock, S, C A McLean, Humphreys, M.K., M K Schmidt, Gabrieau, V., Arias Pérez, JI, Andrulis, I, Margolin, S, Pankratz, VS, Stevens, KN, Zalutsky, J.V., Ko, Y. D., Mannermaa, A, McLean, C.A., Tollenaar, R. A. E. M., Tollenaar, R.A.E.M., Cox, A., Andrulis, I., Schmutzler, R K, R Hein, Winqvist, R., Cross, S S, Pankratz, V.S., P A Fasching, Chen, X., Easton, D.F., Bernard, L, Ko, Y.D., Pylkäs, K., J Lissowska, Hunter, D. J., Fasching, P. A., Yoo, K. Y., J V Zalutsky, Silva, I.D., Kataja, V., Chenevix-Trench, G., T Brüning, Glendon, G, U Hamann, Hein, R., Thomas, G.D., Van T. Veer, L. J., K Pylkäs, Schmidt, MK, kConFab Investigators +417 morecore +1 more sourcePatients' and oncologists' views on the treatment and care of advanced ovarian cancer in the UK:results from the ADVOCATE study [PDF]
, 2013 Background:Most patients presenting with advanced ovarian cancer (AOC) eventually relapse. Symptom palliation, maintenance of quality of life (QoL) and prolongation of life are primary therapeutic goals.Methods:Sixty-six UK oncologists completed an ...Monson, K, Susan Catt (4461673), S Banerjee (9892436), V Jenkins, I Solis-Trapala (7775843), I Solis-Trapala, C Gourley, A Montes (16163120), Jenkins, V, L Fallowfield, Montes, A, S Catt, K Monson, K Monson (13453767), Lesley Fallowfield (4461436), C Gourley (16163117), Valerie Jenkins (4460407), Gourley, C, S Banerjee, A Montes, Catt, S, Fallowfield, L, Banerjee, S, Solis-Trapala, I +23 morecore +1 more sourceMolecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer. [PDF]
, 2023 PURPOSE: We present the results of a post hoc tumor tissue analysis from the phase 3 MILO/ENGOT-ov11 study (NCT01849874). PATIENTS AND METHODS: Mutation/copy-number analysis was performed on tissue obtained pre-randomization.Oehler, MK, Moore, KN, Monk, BJ, Westermann, A, Romero, I, Marth, C, Kristensen, G, Farley, J, Drill, E, Grisham, RN, Kalbacher, E, Iyer, G, Clamp, A, Banerjee, S, Colombo, N, Ray-Coquard, I, Churruca, C, Mirza, MR, Cibula, D, Del Campo, JM, Oza, AM, Pignata, S, Berger, R, Vergote, I, Hilpert, F, Aghajanian, C, O'Malley, DM, Coleman, RL, Sehouli, J, Vuylsteke, P +29 morecore +1 more sourceAge-Specific Cancer Mortality in the US During the COVID-19 Pandemic, March to December 2020. [PDF]
BACKGROUND: It is important to understand the impact of the COVID-19 pandemic on cancer death rates in 2020 in the US. We estimated whether there were larger-than-expected changes in cancer mortality rates from March to December 2020 after accounting for Shiels, MS, Berrington de González, A, Haque, AT, Freedman, ND, Kim, H-R, Albert, PS +5 morecore +1 more sourceMir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer [PDF]
, 2013 <p>Background: Aberrant mitogen/extracellular signal-regulated kinase 5 (MEK5)–extracellular signal-regulated protein kinase 5 (ERK5)-mediated signalling has been implicated in a number of tumour types including prostate cancer (CaP). The mechanism Kalna, G., Yang, Z H, Z H Yang, Leung, H.Y., Scardino, P, L B Singh, Singh, LB, H Møller, C Cooper, Cuzick, J, J Fleming, Singh, L.B., Yang, Z.H., I Ahmad, G Kalna, D M Berney, Singh, L. B., Scardino, P., Leung, H Y, Ahmad, I., Møller, H; id_orcid, J Cuzick, Berney, D. M., Cuzick, J., Møller, H., Leung, H. Y., Berney, DM, Fisher, G., Fleming, J., Cooper, C., Leung, HY, Kalna, G, P Scardino, Yang, Z. H., Berney, D.M., Fisher, G, Cooper, C, Møller, H, Ahmad, I, G Fisher, Yang, ZH, Singh, L B, Fleming, J, H Y Leung, Berney, D M +44 morecore +1 more sourceDriver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast Cancer [PDF]
, 2018 Summary: Two reports in this issue of Cancer Discovery outline how the genomic composition of tumors, including the presence of intragenic gene fusions, could inform the selection of treatment approaches in aggressive forms of the disease. Cancer Discov; Natrajan, R, Tutt, ANJ, Christopher J. Lord, Lord, CJ, Andrew N.J. Tutt, Rachael Natrajan +5 morecore +1 more source
